Ahmed Z, Kragie L,Connor JA. 1980 Stoichiometry and apparent dissociation
constant of the calcium-arsenazo III reaction under physiological conditions.
Biophysical
Journal 32: 907-920
Kragie L, Doyle D. 1992 Benzodiazepines inhibit temperature-dependent
[125]I-L-triiodo-thyronine accumulation into human liver, human neuroblast
and rat pituitary cell lines. Endocrinology 130: 1211-1216
Kragie L, Sekovski B. 1992 Theophylline -- an alternative therapy
for bradyarrhythmia in the elderly. Pharmacotherapy 12:324-330
Kragie L. 1992 Requisite structural characteristics for benzodiazepine
inhibition of triiodothyronine uptake into a human liver cell line. Life
Sciences, Pharmacology Letters 51: PL83-PL88
Kragie L. 1993 Neuropsychiatric implications of thyroid hormone-benzodiazepine interactions. Endocrine Research 19: 1-32
Kragie L, Kwon YW, Smiehorowski R. 1993 Rat cardiac calcium channels
and their relationships with b-adrenergic and muscarinic receptors in hypothyroidism. Endocrine Research19: 57-71
Kragie L, Smiehorowski R. 1993 Measures of skeletal muscle calcium
channels and acetylcholine receptors in thyroidectomized rats. Endocrine
Research 19: 207-219
Kragie L, Stock ME. 1994 Acetylcholinesterase activity in fast-twitch
skeletal muscle from thyroidectomized rats. Endocrine
Research 20: 47-57
Kragie L, Forrester ML, Cody V, McCourt M. 1994 Computer-assisted
molecular modeling of benzodiazepine and thyromimetic inhibitors of the
HepG2 iodothyronine transporter. Molecular Endocrinology 8: 382-391
Kragie L, Smiehorowski R. 1994 Altered peripheral benzodiazepine
receptor binding in cardiac and liver tissues from thyroidectomized rats.
Life
Sciences 55 (24): 1911-1918
Kragie L. 1994 Membrane iodothyronine transporters part I: review
of physiology. Endocrine Research 20 (4): 319-342
Kragie L. 1996 Membrane iodothyronine transporters part II: review
of protein biochemistry. Endocrine Research 22 (2):95-119
Lukas SE, Sholar M, Lundahl J, Lamas X, Kouri E, Wines JD, Kragie L,
Mendelson JH. 1996 Sex differences in plasma cocaine levels and subjective
effects after acute cocaine administration in human volunteers. Psychopharmacology
125: 346-354
Kragie L. 1999 Today's Telemedicine. Healthcare
Trends Report 13(6): 1-15
Kragie L, Turner SD, Patten CJ, Crespi CL, Stresser DM. 2002
Assessing pregnancy risks of azole antifungals using a high throughput
aromatase inhibition assay. Endocrine Research 28 (3): 129-140
Kragie L. 2002 Aromatase in primate pregnancy: a review. Endocrine
Research 28 (3): 121-128
Kragie L. 2006 Another Reorganization at FDA: Office of Translational Sciences. What It Means For You. Life Sciences Due Diligence & Regulatory Analysis, Vol 1; Issue 1
Abstracts of Presentations at Scientific Society Meetings:
Kragie L, Ahmed Z, Connor JA, Davis PJ. Neuronal CaATPase activity
and changes in intracellular Ca2+ induced by short-term exposure to thyroid
hormone. Society for Neuroscience Annual Mtg, 1985 [Abstract #164.10]
Kragie L, Schoenl M, Lawrence WD, Davis PJ. CNS effects of thyroid
hormone involve stimulation of cytosolic protein kinase activity. Society
for Neuroscience Annual Mtg, 1987 [Program Abstract #182.7]
Kragie L, Doyle D. Benzodiazepines inhibit triiodothyronine transport
into human liver cell line. Society for Neuroscience Annual Meeting, 1990
[Program Abstract #36.19]
Kragie L, Doyle D. Benzodiazepine inhibition of triiodothyronine
uptake into human liver cell line has a unique structure activity relationship.
Society for Neuroscience Annual Mtg, 1991 [Abstract #537.10]
Kragie L, Forrester ML, Cody V. Structural characteristics of benzodiazepine
compounds which inhibit triiodothyronine cellular uptake. The 74th Annual
Endocrine Society Mtg, 1992 [Abstract #428]
Kragie L, Forrester ML, Cody V. Comparison of benzodiazepine inhibitors
of thyroid hormone cellular uptake to thyroid hormones, using crystallographic
computer modeling. 23rd National Medicinal Chemistry Symposium, Division
American Chemical Society, 1992 [Abstract]
Kragie L, Smiehorowski R. Peripheral benzodiazepine receptor binding
in hypothyroid rat ventricles. Society for Neuroscience Annual Meeting,
1992 [Abstract #486.15]
Kragie L, Smiehorowski R, Goonawardena D. Putative iodothyronine
transporter membrane proteins from liver and brain as identified with antibodies
and ligand affinity chromatography. The 75th Annual Endocrine Society Mtg,
1993 [Abstract #818]
Lui Y, Kragie L, Smiehorowski R, Marfella C, Lakshmanan M. Polyclonal
antibodies to benzodiazepine binding proteins decrease triiodothyronine
uptake into mouse neuroblasts. American Federation for Clinical Research
Mtg, 1994 [Abstract]
Lakshmanan M, McCourt M, Lui Y, Kragie L. Thyroid hormone plasma
membrane transport: structural homology and binding site interactions with
aminoacids and benzodiazepines. The American Thyroid Association Annual
Mtg, 1994. [Abstract]
Kragie L, McCourt M, Lakshmanan M. Modeling the iodothyronine and
aminoacid transport sites in mouse neuroblastoma cells. 77th Annual Endocrine
Society Mtg, 1995 [Abstract #P3-422] p 574
Kragie L, Amri H, Gore L, Flockhart D, Papadopoulos V. Cytochrome
P450 Aromatase: An In Vitro Screening Tool for Drug-Steroid Interactions.
The 10th International Congress of Endocrinology, 1996 [Abstract #P3-480]
p 874
Stresser DM, Turner SD, Ho T, Crespi CL, Kragie L. Aromatase Inhibition
by Azole Drugs: Assessing Pregnancy Risks. Society of Toxicology
Annual Meeting, Nashville TN, March 2002
Kragie L, Stresser DM, Turner SD, Patten CJ, Crespi CL. Assessing
pregnancy risks using a high throughput aromatase inhibition assay. ASCPT Annual Meeting, Atlanta GA, March 2002. [Abstract #TPII-94] Clinical
Pharmacology & Therapeutics Feb 2002; 71(2): P67
Castelli C, Fotso J, Tiano D, Kragie L. An Evaluation of the Pharmacokinetic Profile of Naritriptan in Rats Following the Oral Administration of Naritriptan Combined with Eligen Carriers (Functional Excipients).
ASCPT Annual Meeting, Orlando FL, April 2008. [Abstract #PI-73]
Clinical Pharmacology & Therapeutics March 2008; 83(suppl): S32
Emisphere Technologies is INFRINGING the BioMedWorks(R) trademark. They have NO association with BioMedWorks(R) LLC. Dr. Kragie is NOT an author on the following abstracts:
Canadian Journal of Clinical Pharmacology Fall 2008 15(3): e718
The AAPS Journal June 2008 #776: 10(S1)
The FASEB Journal 2008; 22:lb795
Presentations as an Invited Speaker
NY State Div of Substance Abuse Services, Buffalo, Workshop on "Women and
AIDS"
Testimony before the Public Health Committee, Erie County Legislature,
Buffalo; "Recommendation to Establish an AIDS Advisory Council for Erie
County"
Buswell Seminar, SUNY at Buffalo School of Medicine, "Thyroid Hormone Effects
on Calcium Dependent Kinase and Phosphatase Activities in Rabbit Brain."
Buswell Seminar, SUNY Buffalo School of Medicine, "Calcium Channel Agonist
Affects CNS CaATPase Activity."
Neuroscience Series, Buffalo, VA Med Center, "Molecular Pharmacology of
Agonist-Induced Regulation of the Benzodiazepine Receptor"
Univ of Illinois, Department of Physiology, Urbana, "Structure Activity
Relationship for Inhibition of Thyroid Hormone Uptake"
Alcohol & Drug Abuse Res Center, Harvard Medical School, "Benzodiazepines,
are they Thyroid Hormone Analogs?"
Neuroscience Seminar, Mailman Research Center, Harvard Medical School,
"Studies of the Iodothyronine Transporter"
Dept of Pharmacology, Meharry Medical School, "Thyroid Hormones and Benzodiazepines: Cellular Sites for Interaction"
Dept of Clinical Pharmacology, Georgetown Univ Med Center, Washington DC.
"Development of the Thyroid Hormone Transporter Pharmacophore using Molecular
Modeling of Benzodiazepine and Amino Acid Inhibitors"
Panel Speaker for FDA Workshop, Rockville, Gender Studies in Product
Development: Scientific Issues and Approaches. "Hormonal Influences
on Drug Metabolism/Effect"
Institute of Medicine Workshop, "Roundtable on research and Development
of Drugs, Biologics, and Medical Devices" NRC Washington DC
Panel Speaker on Genomic and Medical Informatics, Maryland B2B, Rockville, MD
"Bio-Tech in Maryland, An Investment Symposium"
Traditions of Excellence Award Ceremony, Oak Park River Forest High School, Oak
Park IL, "Defining Traditions of Excellence" and "Words of Wisdom."
Co-chair & Speaker, ASCPT Workshop Orlando FL, "Interaction of Drugs with Estrogen Endocrinology"
Seminar Merck Pharmaceuticals, Wayne NJ, "Azole Aromatase Inhibitors and their
Clinical Implications"
PATENTS
Kragie L
PCT Application filed OCT10/2001, published APR18/2002
PCT International Pub Number: WO 02/30355 A2
USPTO #10/474,838; OCT 11/2000 Provisional Patent
CANADA # 2,462,081
Title: COMPOSITION AND METHOD OF ALLEVIATING ADVERSE SIDE EFFECTS AND/OR ENHANCING EFFICACY OF AGENTS THAT INHIBIT AROMATASE
Abstract: This disclosure describes compositions and methods of use of compositions, that can replace the role of estrogens in the functions of human and other animals, when these humans or animals are under the influence of compounds, devices and biologics that can inhibit the activity of aromatase enzyme (estrogen synthetase).
Emisphere Technologies is INFRINGING the BioMedWorks(R) trademark. They have NO association with BioMedWorks(R) LLC and NO Power of Attorney to represent BioMedWorks(R) or Dr. Kragie.
Dr. Kragie is NOT an inventor of the PCT application published on 07 MAY 2009: WO 2009/059188 A1 nor the issued US patent 8,022,048
